LEHI, Utah and LOUISVILLE, Ky., Nov. 18, 2025 /PRNewswire/ -- Waystar Holding Corp. (Nasdaq: WAY), a provider of leading healthcare payment software, today announced that Chief Executive Officer Matt Hawkins and Chief Financial Officer Steve Oreskovich will participate in three upcoming investor conferences:
Waystar will provide live webcasts of the Citi and Barclays fireside chats on its Investor Relations website at https://investors.waystar.com/news-events/events. Recordings will also be available on the site after the events.
About Waystar
Waystar's mission-critical software is purpose-built to simplify healthcare payments so providers can prioritize patient care and optimize their financial performance. Waystar serves approximately 30,000 clients, representing over 1 million distinct providers, including 17 of 20 institutions on the U.S. News Best Hospitals list. Waystar's enterprise-grade platform annually processes over 6 billion healthcare payment transactions, including over $1.8 trillion in annual gross claims and spanning approximately 50% of U.S. patients. Waystar strives to transform healthcare payments so providers can focus on what matters most: their patients and communities. Discover the way forward atwaystar.com.
Media Contact
Kristin Lee
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Contact
Sue Dooley
This email address is being protected from spambots. You need JavaScript enabled to view it.

| Last Trade: | US$36.18 |
| Daily Change: | -0.86 -2.32 |
| Daily Volume: | 481,225 |
| Market Cap: | US$6.920B |
October 29, 2025 October 01, 2025 September 10, 2025 September 09, 2025 | |

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load